• Something wrong with this record ?

Impact of breast cancer neoadjuvant chemotherapy on plasma and urine amino acid profile, plasma proteins and nitrogen metabolism

M. Dastych, M. Holánek, J. Gottwaldová, Z. Čermáková, A. Mikušková

. 2024 ; 84 (4) : 237-244. [pub] 20240627

Language English Country England, Great Britain

Document type Journal Article, Observational Study

Persistent link   https://www.medvik.cz/link/bmc24019866

Neoadjuvant chemotherapy (NAC) is the preferred treatment option in locally advanced breast cancer (BC). The administration of NAC is associated with a wide range of adverse effects. This pilot observational prospective study examined the effect of NAC using anthracycline + cyclophosphamide (AC) followed by paclitaxel (PTx) on a portfolio of 22 plasma and urinary amino acids, plasma proteins (albumin, prealbumin, transferrin), and products of nitrogen metabolism (urea, creatinine, uric acid) in plasma and urine. Plasma and 24-h urine samples were obtained from ten patients with early breast cancer (N1-3 N0-2 M0), at the following time points: before the start of NAC and during the AC/PTx treatment period (a total of 8 measurements at three-weekly intervals). Amino acids were analyzed using ion exchange chromatography. There were no significant differences in the measured parameters in plasma and urine between pre-NAC and during AC- and PTx-treatment. No trend was detected. A significant difference in the portfolio of plasma and urinary amino acids was found only in the pre-treatment period compared to the control group. Levels of eight plasma amino acids (8/22) were significantly reduced and those of nine urine amino acids were increased (9/22). Nitrogenous catabolites in plasma and urine were not indicative of increased protein catabolism during the anthracycline and taxane treatment periods. A slightly positive nitrogen balance was accompanied by an average weight gain of 3.3 kg (range 0-6 kg). The AC/PTx treatment regimen did not cause significant changes in the monitored laboratory parameters.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019866
003      
CZ-PrNML
005      
20241024111047.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/00365513.2024.2369982 $2 doi
035    __
$a (PubMed)38934425
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Dastych, Milan $u Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Laboratory Method, Faculty of Medicine Masaryk University, Brno, Czech Republic $1 https://orcid.org/000000027187080X
245    10
$a Impact of breast cancer neoadjuvant chemotherapy on plasma and urine amino acid profile, plasma proteins and nitrogen metabolism / $c M. Dastych, M. Holánek, J. Gottwaldová, Z. Čermáková, A. Mikušková
520    9_
$a Neoadjuvant chemotherapy (NAC) is the preferred treatment option in locally advanced breast cancer (BC). The administration of NAC is associated with a wide range of adverse effects. This pilot observational prospective study examined the effect of NAC using anthracycline + cyclophosphamide (AC) followed by paclitaxel (PTx) on a portfolio of 22 plasma and urinary amino acids, plasma proteins (albumin, prealbumin, transferrin), and products of nitrogen metabolism (urea, creatinine, uric acid) in plasma and urine. Plasma and 24-h urine samples were obtained from ten patients with early breast cancer (N1-3 N0-2 M0), at the following time points: before the start of NAC and during the AC/PTx treatment period (a total of 8 measurements at three-weekly intervals). Amino acids were analyzed using ion exchange chromatography. There were no significant differences in the measured parameters in plasma and urine between pre-NAC and during AC- and PTx-treatment. No trend was detected. A significant difference in the portfolio of plasma and urinary amino acids was found only in the pre-treatment period compared to the control group. Levels of eight plasma amino acids (8/22) were significantly reduced and those of nine urine amino acids were increased (9/22). Nitrogenous catabolites in plasma and urine were not indicative of increased protein catabolism during the anthracycline and taxane treatment periods. A slightly positive nitrogen balance was accompanied by an average weight gain of 3.3 kg (range 0-6 kg). The AC/PTx treatment regimen did not cause significant changes in the monitored laboratory parameters.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a nádory prsu $x farmakoterapie $x krev $x moč $7 D001943
650    12
$a dusík $x moč $7 D009584
650    12
$a neoadjuvantní terapie $7 D020360
650    _2
$a lidé středního věku $7 D008875
650    12
$a aminokyseliny $x moč $x krev $7 D000596
650    12
$a paclitaxel $x terapeutické užití $x aplikace a dávkování $7 D017239
650    12
$a cyklofosfamid $x terapeutické užití $7 D003520
650    12
$a krevní proteiny $x metabolismus $x analýza $7 D001798
650    _2
$a dospělí $7 D000328
650    _2
$a prospektivní studie $7 D011446
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a senioři $7 D000368
650    _2
$a pilotní projekty $7 D010865
650    _2
$a antracykliny $x terapeutické užití $x aplikace a dávkování $7 D018943
650    _2
$a kreatinin $x moč $x krev $7 D003404
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Holánek, Miloš $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Gottwaldová, Jana $u Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Čermáková, Zdenka $u Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Mikušková, Alena $u Department of Paediatric Haematology and Biochemistry, Children's University Hospital Brno, Brno, Czech Republic
773    0_
$w MED00010597 $t Scandinavian journal of clinical and laboratory investigation $x 1502-7686 $g Roč. 84, č. 4 (2024), s. 237-244
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38934425 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111041 $b ABA008
999    __
$a ok $b bmc $g 2202215 $s 1231839
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 84 $c 4 $d 237-244 $e 20240627 $i 1502-7686 $m Scandinavian journal of clinical and laboratory investigation $n Scand J Clin Lab Invest $x MED00010597
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options